Toxicology is often called the “science of safety,” and for good reason. The field is essential in moving potential new drugs from the lab to the clinic, enabling drug sponsors to predict whether any components of the drug may cause harm to patients. And if a chemical is deemed harmful, toxicologists can figure out why.
Innovation is percolating around new approaches to treating injuries that result from chemical, biological, radiological and nuclear defense, as well as other public health emergencies. With funding from BARDA and other government entities, commercial pharmaceutical and biotechnology firms are seeking to repurpose existing molecules to save more lives.
The established cancer drug topotecan may hold promise as a more targeted therapy for patients with small-cell lung cancer (SCLC), according to the results of a study presented by Lovelace Biomedical scientists. The findings are significant, as lung cancer remains one of the leading causes of cancer deaths worldwide. New treatment options are direly needed, […]
For preclinical pharmacology and toxicology studies to succeed, it’s essential that investigators and their teams use best practices for animal enrichment and environmental enhancement. Animal stress — which can stem from lack of trust in the researchers or an inability to express natural, species-specific behaviors — can compromise study data.
Inhaled medicines play an essential role in treating respiratory conditions and many other diseases, from pulmonary fibrosis to asthma. However, a dose of inhaled medicine often results in a cough — an adverse reaction that can be both uncomfortable and counterproductive. It’s a reaction that drug developers seek to avoid as they develop the next […]
In a key study published in Human Gene Therapy Clinical Development, Lovelace Biomedical researchers found that delivering AAV gene therapy for cystic fibrosis by inhalation was both feasible and safe.